User:Mr. Ibrahem/Sacituzumab govitecan

Sacituzumab govitecan, sold under the brand name Trodelvy, is a medication used to treat triple-negative breast cancer and urothelial cancer. Specifically it is used in cases were the cancer has spread and other treatments have failed. It is given by injection into a vein.

Common side effects include nausea, low neutrophils, diarrhea, tiredness, low red blood cells, vomiting, hair loss, constipation, decreased appetite, rash and abdominal pain. Other side effects may include infertility and anaphylaxis. Use in pregnancy or breastfeeding may harm the baby baby. It is a TROP-2-directed antibody joined to a topoisomerase inhibitor.

Sacituzumab govitecan was approved for medical use in the United States in 2020. As of 2021 it is not available in Europe due to a lack of supply. It costs about 310,500 USD per year as of 2021 for a 70 kg person.